Red Clover and Bone Density
Bone loss after menopause is real, fast and consequential. In the few years surrounding the final menstrual period, women can lose bone at several times their previous rate, and the fractures that follow — particularly hip fractures — carry serious consequences for independence and survival. It is therefore entirely understandable that a herb marketed as a natural source of plant estrogen would be looked at as a possible bone protector.
The evidence for that is weaker than the marketing implies, and the reason is instructive. Bone research uses three very different kinds of endpoint, and supplement claims routinely slide between them as if they were the same thing. This page keeps them separate: what red clover does to bone turnover markers (a blood or urine chemistry measurement), what it does to bone mineral density (an actual scan), and what it does to fractures (the only endpoint anyone truly cares about). Red clover has some evidence for the first; for the second, two one-year placebo-controlled trials and one 12-week trial found less bone loss at the lumbar spine than with placebo, with mixed results at the hip; and there is no evidence at all for the third.
Table of Contents
- Why Bone Is Lost After Menopause
- How Estrogen Protects Bone
- Three Endpoints That Are Not the Same Thing
- What Isoflavones Do to Bone Cells
- Animal Studies
- The Human Density Trials
- Fermented Extracts and the Osteopenia Trial
- Pooled Analyses Across Isoflavone Formulations
- What Actually Protects Bone
- The Honest Verdict
- Key Research Papers
- Safety and Disclaimer
- Connections
- Featured Videos
Why Bone Is Lost After Menopause
Bone is not inert scaffolding. It is continuously demolished and rebuilt by two cell populations working in opposition: osteoclasts, which dissolve old bone, and osteoblasts, which lay down new bone. In a healthy adult these are roughly balanced, and the whole skeleton is quietly replaced over about a decade.
Estrogen is one of the principal brakes on the demolition side. When estrogen falls at menopause, osteoclasts live longer and work harder, the rebuilding side cannot keep pace, and net bone is lost. The loss is not gradual and even — it accelerates sharply in the years around the final period, with the fastest phase typically spanning the year before through several years after, and then settles to a slower age-related decline.
Trabecular bone — the sponge-like interior found in the spine, hip and wrist — is metabolically busier than the dense cortical shell and is lost first. That is why vertebral and wrist fractures show up earlier in the sequence and hip fractures later. It also means the spine is where a bone-density study will detect a change soonest, which is why trials measure it there.
How Estrogen Protects Bone
Estrogen restrains bone resorption through several routes. It reduces the production of signalling molecules that recruit and activate osteoclasts, increases the decoy receptor that intercepts the principal osteoclast-activating signal, and promotes osteoclast death once their work is done. It also supports osteoblast survival. The net effect is a slower, better-coupled remodelling cycle.
Hormone therapy demonstrates this convincingly: it reduces bone loss and, in randomized trials, reduces fractures — a point covered on Bone Loss Prevention and hormone replacement therapy (HRT). Evidence tier: large randomized clinical trials with fracture endpoints.
The question for red clover is whether a weak plant estrogen, acting mainly at estrogen receptor beta and at a small fraction of estradiol's potency, can reproduce any clinically useful share of that. Bone cells do carry estrogen receptor beta, so the target exists. Whether the signal is strong enough is exactly what the trials were built to find out.
Three Endpoints That Are Not the Same Thing
This section is the key to reading any bone supplement claim critically.
- Bone turnover markers. Blood or urine measurements of fragments released as bone is broken down or built — collagen crosslinks such as CTX and NTX for resorption, P1NP and bone-specific alkaline phosphatase for formation. They respond within weeks, which makes them cheap and convenient for short trials. They are a snapshot of activity, not a measure of how much bone you have.
- Bone mineral density (BMD). Measured by DXA scan, usually at the lumbar spine and hip. This is an actual quantity of mineral. It moves slowly — a study generally needs at least a year to detect a real change — and it is a far better predictor of fracture than turnover markers.
- Fractures. The outcome that matters. Detecting a fracture difference requires thousands of participants followed for years. No red clover trial has ever come close to that scale.
The gap between markers and fractures is not hypothetical. Drugs have been developed that moved turnover markers in the desired direction and then failed, or caused harm, when tested against real outcomes. A supplement that shifts a bone marker over twelve weeks has demonstrated biological activity. It has not demonstrated that it prevents a single broken bone. Every marketing claim built on marker data should be read with that sentence in mind.
What Isoflavones Do to Bone Cells
In cell culture, isoflavones including genistein and daidzein — the two active products of red clover's biochanin A and formononetin — show effects consistent with a mild estrogenic action on bone: reduced osteoclast formation and activity, and in some systems support for osteoblast differentiation. Biochanin A and formononetin themselves have been studied directly in bone cell models with broadly similar findings.
These results are genuinely interesting and genuinely limited. Cell-culture experiments use concentrations that may exceed what a capsule produces in human blood, they bypass digestion and liver metabolism entirely, and isolated bone cells behave differently from bone in a living skeleton subject to mechanical loading and systemic hormones. A useful entry point to this literature is a PubMed topic search on biochanin A, formononetin and bone cells. Evidence tier: preliminary, in vitro.
Animal Studies
The standard animal model for postmenopausal bone loss is the ovariectomized rat, which loses bone rapidly once its ovaries are removed. Red clover isoflavones have been tested in it. Effects of phytoestrogenic isoflavones from red clover (Trifolium pratense L.) on experimental osteoporosis (Phytotherapy Research, 2007) examined red clover isoflavones in this model — PubMed PMID: 17117453. Related work, Effect of an isoflavones-containing red clover preparation and alkaline supplementation on bone metabolism in ovariectomized rats (Clinical Interventions in Aging, 2009), tested a red clover preparation on bone metabolism in the same model — PubMed PMID: 19503771. Evidence tier: preliminary, animal.
Animal bone studies are a reasonable screening step and a poor basis for a human claim. Rodents lose bone far faster than women do, doses per kilogram are often much higher than a human supplement provides, and the ovariectomized rat has an unhappy history of predicting benefits that did not replicate in people. These studies justify running human trials. They do not substitute for them — and in red clover's case, the human trials were run.
The Human Density Trials
The single most important human study is The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial (The American Journal of Clinical Nutrition, 2004). It enrolled 205 women aged 49–65 (177 completed) and gave a red clover-derived isoflavone supplement — a daily 26 mg biochanin A, 16 mg formononetin, 1 mg genistein and 0.5 mg daidzein — or placebo for one full year, measuring bone density at baseline and after 12 months — the right endpoint, over an adequate duration, in a properly blinded design. Loss of lumbar spine bone mineral content and bone mineral density was significantly lower in the women taking the isoflavone supplement than in those taking placebo (P = 0.04 and P = 0.03). There was no significant effect on hip bone mineral content or density, or on markers of bone resorption; bone formation markers rose in the postmenopausal women taking the supplement. The authors concluded that isoflavones have a potentially protective effect on the lumbar spine in women. PubMed PMID: 14749241. Evidence tier: randomized clinical trial; less bone loss at the spine, no effect at the hip.
This trial is the reason the honest summary of red clover and bone is limited rather than negative: the best-designed study, using bone density over a full year, found less bone loss at the spine but no effect at the hip, and it did not measure fractures.
Earlier and smaller work had also been encouraging. A 2001 trial of a red clover isoflavone supplement (Menopause, 2001) randomised 46 postmenopausal women to 28.5 mg, 57 mg or 85.5 mg of isoflavones daily for 6 months, with no placebo group running alongside. Bone mineral density of the forearm (proximal radius and ulna) rose by 4.1% with 57 mg/day (p = 0.002) and by 3.0% with 85.5 mg/day (p = 0.023); the response with 28.5 mg/day was not significant. Serum high-density lipoprotein (HDL) cholesterol rose by 15.7–28.6% and apolipoprotein B fell by 11.5–17.0%. The authors state that the results are interpreted cautiously because of the absence of a simultaneously studied control group — PubMed PMID: 11449083. It was small and short, and it is the kind of preliminary result that larger trials exist to test. Evidence tier: small dose-comparison trial without a placebo group, positive, not replicated at scale.
A shorter modern study, Intake of Novel Red Clover Supplementation for 12 Weeks Improves Bone Status in Healthy Menopausal Women (Evidence-Based Complementary and Alternative Medicine, 2015), gave 60 menopausal women a daily red clover extract containing 37.1 mg isoflavones, or placebo. Only the women receiving placebo had a decline in bone mineral density (p < 0.01) and T-score at the lumbar spine; the bone-breakdown marker CTx fell 9.94% in the red clover group, which was not significant — PubMed PMID: 26265926. This is a density result measured by scan, but twelve weeks is a short period for scan-measured bone change. Evidence tier: short randomized placebo-controlled trial.
Fermented Extracts and the Osteopenia Trial
The most substantive positive human bone result comes from the fermented-extract line of research. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial (The American Journal of Clinical Nutrition, 2017) used a fermented red clover extract in women who already had osteopenia — reduced bone density short of osteoporosis — and reported reduced bone mineral density loss compared with placebo, together with changes in estrogen metabolism. PubMed PMID: 28768651. Evidence tier: randomized clinical trial, positive, single and small.
The numbers: in this 12-month, double-blind trial, 78 postmenopausal women with osteopenia took either a red clover extract rich in isoflavone aglycones (60 mg a day) with probiotics, or a masked placebo; all of them also took calcium (1200 mg/d), magnesium (550 mg/d) and calcitriol (25 µg/d). Bone mineral density loss was smaller with the red clover extract at the lumbar spine (L2–L4: −0.99% vs −2.2%), the femoral neck (−1.04% vs −3.05%) and the trochanter (−0.67% vs −2.79%). The bone-breakdown marker CTx fell 9.40% with the extract and 6.76% with placebo, equol-producer status rose, and the extract was well tolerated with no adverse events.
The logic behind fermenting is the same as on the menopause page: fermentation converts the plant's isoflavones into more bioavailable and more receptor-active forms during manufacture, rather than relying on the individual's gut bacteria to do it. If bioavailability is what earlier trials lacked, a fermented product might succeed where a conventional extract failed.
Three cautions apply, and they are not small. The trial was modest in size and has not been independently replicated by other groups. It measured density change over 12 months, not fractures, and every woman in both groups also took calcium, magnesium and calcitriol, so the result is the extract and probiotics on top of that background. And the product tested is a specific fermented preparation, not the standard red clover extract sold in most shops — buying an ordinary bottle on the strength of this study means buying something that was not what the study tested.
Pooled Analyses Across Isoflavone Formulations
A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women (The American Journal of Clinical Nutrition, 2017) pooled isoflavone bone data across different formulations and treated formulation and bioavailability as the central variable rather than a nuisance — PubMed PMID: 28768649. Evidence tier: systematic review of randomized trials.
It pooled 26 randomised trials with 2652 women. Isoflavone treatment gave a small but significantly greater bone-density change than control at the lumbar spine (weighted mean difference 0.01; 95% CI 0.01 to 0.02) and at the femoral neck (18 trials, 1604 women; 0.01; 95% CI 0.00 to 0.02). In the 5 trials (682 women) that gave isoflavones in aglycone form, the effect at the spine was larger (0.04; 95% CI 0.02 to 0.05); when only trials of mainly glycoside-form products were included, the protective effect disappeared. The authors conclude that isoflavone treatments exert a moderately beneficial effect against estrogen-deficient bone loss in women, and that the effect appears to depend on whether the isoflavones are in aglycone form.
That framing is the most useful contribution the pooled literature makes. It suggests that "which isoflavone preparation, delivering which metabolites, to whom?" matters as much as "do isoflavones help bone?" — the pooled benefit was larger for aglycone-form products and absent for glycoside-form products.
A caveat on reading this literature: much of the isoflavone bone research involves soy-derived preparations rather than red clover. Those trials are legitimate scientific context for how isoflavones behave in bone, but they are not evidence about red clover specifically, and pooled analyses that mix sources should be read with that in mind.
What Actually Protects Bone
Because the red clover evidence is limited, it is worth being concrete about what has stronger evidence.
- Adequate calcium and vitamin D. The nutritional foundation, best met through food where possible. See Calcium for Bone Health and Vitamin D3 for Bone Health. Evidence tier: extensive randomized and observational evidence.
- Weight-bearing and resistance exercise. Bone responds to mechanical load. Walking, stair climbing, and particularly progressive resistance training stimulate bone directly, and improved strength and balance reduce falls — which is how most fractures actually happen. Evidence tier: randomized trials.
- Not smoking, and moderate alcohol intake. Both smoking and heavy drinking are established independent risk factors for low bone density and fracture. Evidence tier: consistent epidemiology.
- Adequate protein and overall nutrition. Bone is roughly half protein by volume, and undernutrition and low body weight are significant fracture risks.
- Magnesium and vitamin K2 play supporting roles in bone metabolism, with evidence weaker than calcium and vitamin D but a coherent rationale. See Magnesium and Vitamin K2.
- Prescription bone medication when indicated. For established osteoporosis or high fracture risk, bisphosphonates, denosumab, anabolic agents and hormone therapy have randomized evidence with fracture endpoints — the evidence tier red clover has never reached. See Osteoporosis.
- Fall prevention. Vision checks, reviewing medications that cause dizziness, removing home trip hazards, balance training. Unglamorous and highly effective.
A DXA scan is how you find out where you actually stand. Guessing, or hoping a supplement is handling it, is the failure mode this section exists to prevent.
The Honest Verdict
Red clover is not an established treatment for osteoporosis or osteopenia. Two year-long placebo-controlled trials measuring actual bone mineral density found less bone loss at the lumbar spine with red clover isoflavones: one found no effect at the hip, and the other — in women with osteopenia who also took calcium, magnesium and calcitriol — found less loss at the hip too. A 2017 meta-analysis of 26 isoflavone trials, much of it soy rather than red clover research, found a moderately beneficial effect against bone loss. The other positive human results come from small, short studies or from surrogate markers. No red clover study has ever measured a fracture.
The fermented-extract osteopenia result is the strongest thing the herb has, and it has not been independently replicated. On the current evidence, red clover may be a minor supporting player in bone health; no study shows that it can replace the measures listed above.
The practical risk here is not that red clover harms bone. It is that someone at genuine fracture risk takes a supplement, feels they have addressed the problem, and does not get the scan, the exercise programme or the prescription that would actually have helped. That substitution is the real harm.
Key Research Papers
- Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial — The American Journal of Clinical Nutrition, 2004. The one-year density trial; less bone loss at the lumbar spine, no effect at the hip. PubMed PMID: 14749241
- Lambert MNT, Thybo CB, Lykkeboe S, et al. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial — The American Journal of Clinical Nutrition, 2017. PubMed PMID: 28768651
- Lambert MNT, Hu LM, Jeppesen PB. A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women — The American Journal of Clinical Nutrition, 2017. PubMed PMID: 28768649
- Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism — Menopause, 2001. PubMed PMID: 11449083
- Thorup AC, Lambert MN, Kahr HS, Bjerre M, Jeppesen PB. Intake of Novel Red Clover Supplementation for 12 Weeks Improves Bone Status in Healthy Menopausal Women — Evidence-Based Complementary and Alternative Medicine, 2015. PubMed PMID: 26265926
- Occhiuto F, Pasquale RD, Guglielmo G, Palumbo DR, et al. Effects of phytoestrogenic isoflavones from red clover (Trifolium pratense L.) on experimental osteoporosis — Phytotherapy Research, 2007. Animal model. PubMed PMID: 17117453
- Kawakita S, Marotta F, Naito Y, Gumaste U, et al. Effect of an isoflavones-containing red clover preparation and alkaline supplementation on bone metabolism in ovariectomized rats — Clinical Interventions in Aging, 2009. Animal model. PubMed PMID: 19503771
- Beck V, Rohr U, Jungbauer A. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? — The Journal of Steroid Biochemistry and Molecular Biology, 2005. Receptor pharmacology background. PubMed PMID: 15876415
- Setchell KD, Clerici C. Equol: history, chemistry, and formation — The Journal of Nutrition, 2010. Why bioavailability may differ between individuals. PubMed PMID: 20519412
- PubMed topic search: biochanin A formononetin osteoblast osteoclast bone — the cell-level literature. Run this search
- PubMed topic search: Trifolium pratense bone mineral density randomized — the full human bone record. Run this search
Safety and Disclaimer
Red clover is a phytoestrogen (a plant compound with estrogen-like action) and carries the cautions that follow from that. Pregnancy and breastfeeding are among them. Its estrogen-like action is the concern for people with a history of breast, uterine or ovarian cancer, endometriosis or uterine fibroids, and for people taking hormone therapy, tamoxifen or an aromatase inhibitor. Its coumarin content is the bleeding concern with anticoagulant or antiplatelet medication and around surgery, where roughly two weeks before a scheduled operation is the stopping interval usually given. Full detail is on Red Clover Isoflavones, Hormones and Safety. Bone loss itself is measured by a DXA scan and a fracture-risk assessment; no supplement study replaces those measurements. This page is educational information, not medical advice.
Connections
- All Herbs
- Red Clover (main page)
- Red Clover Benefits Hub
- Red Clover for Menopause and Hot Flashes
- Red Clover Isoflavones, Hormones and Safety
- Osteoporosis
- Menopause
- Bone Loss Prevention and Hormone Replacement Therapy
- Calcium
- Calcium for Bone Health
- Vitamin D3
- Vitamin D3 for Bone Health
- Vitamin K2
- Magnesium
- Black Cohosh and Bone Health
- Rheumatology